ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options. Given the role of epigenetic alterations in AITL lymphomagenesis, the development of drugs targeting epigenetics may present a promising therapeutic approach. Belinostat, a histone deacetylase (HDAC) inhibitor, induced durable partial remission in heavily pretreated relapsed/refractory angioimmunoblastic T‐cell lymphoma, highlighting its potential as an effective therapeutic option when standard treatments and stem cell transplantation are unsuitable.
Labropoulou et al. (Wed,) studied this question.